Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression

Androgen-deprivation therapy (ADT) with newly developed antiandrogen enzalutamide (Enz) may increase the castration-resistant prostate cancer (CRPC) patients survival an extra 4.8 months. Yet eventually most patients may fail with development of Enz resistance. While recent clinical studies indicate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Wu, Gang, Sun, Yin, Xiang, Zhendong, Wang, Keliang, Liu, Bo, Xiao, Guangqian, Niu, Yuanjie, Wu, Denglong, Chang, Chawnshang
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6425037/
https://ncbi.nlm.nih.gov/pubmed/30674872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-1048-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados